SE513082C2 - Användning av taxol i infusionspreparat - Google Patents
Användning av taxol i infusionspreparatInfo
- Publication number
- SE513082C2 SE513082C2 SE9301951A SE9301951A SE513082C2 SE 513082 C2 SE513082 C2 SE 513082C2 SE 9301951 A SE9301951 A SE 9301951A SE 9301951 A SE9301951 A SE 9301951A SE 513082 C2 SE513082 C2 SE 513082C2
- Authority
- SE
- Sweden
- Prior art keywords
- taxol
- infusion
- patients
- treatment
- hours
- Prior art date
Links
- 229930012538 Paclitaxel Natural products 0.000 title claims abstract description 157
- 229960001592 paclitaxel Drugs 0.000 title claims abstract description 157
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title claims abstract description 157
- 238000001802 infusion Methods 0.000 title claims description 133
- 238000002360 preparation method Methods 0.000 title claims 2
- 238000011282 treatment Methods 0.000 claims abstract description 57
- 238000011275 oncology therapy Methods 0.000 claims abstract 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 14
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 10
- 239000000739 antihistaminic agent Substances 0.000 claims description 9
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims description 9
- 230000009467 reduction Effects 0.000 claims description 9
- 229960000520 diphenhydramine Drugs 0.000 claims description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 7
- 229960003957 dexamethasone Drugs 0.000 claims description 7
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 7
- 150000003431 steroids Chemical class 0.000 claims description 7
- 208000003455 anaphylaxis Diseases 0.000 claims description 6
- 229940125715 antihistaminic agent Drugs 0.000 claims description 6
- 229960003291 chlorphenamine Drugs 0.000 claims description 6
- 229960000890 hydrocortisone Drugs 0.000 claims description 5
- 231100000228 neurotoxicity Toxicity 0.000 claims description 5
- 230000007135 neurotoxicity Effects 0.000 claims description 5
- 206010029350 Neurotoxicity Diseases 0.000 claims description 4
- 206010044221 Toxic encephalopathy Diseases 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 claims description 3
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 claims description 3
- -1 cixnetidine Chemical compound 0.000 claims description 3
- 230000002093 peripheral effect Effects 0.000 claims description 3
- 229960004618 prednisone Drugs 0.000 claims description 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 3
- 229940044551 receptor antagonist Drugs 0.000 claims description 3
- 239000002464 receptor antagonist Substances 0.000 claims description 3
- SWECWXGUJQLXJF-BTJKTKAUSA-N Dimetindene maleate Chemical compound OC(=O)\C=C/C(O)=O.CN(C)CCC=1CC2=CC=CC=C2C=1C(C)C1=CC=CC=N1 SWECWXGUJQLXJF-BTJKTKAUSA-N 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 229960002881 clemastine Drugs 0.000 claims description 2
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 claims description 2
- 229940099401 dimethindene maleate Drugs 0.000 claims description 2
- 229960001596 famotidine Drugs 0.000 claims description 2
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 19
- 238000006243 chemical reaction Methods 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 6
- 238000002483 medication Methods 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 description 59
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 26
- 238000009101 premedication Methods 0.000 description 23
- 238000000034 method Methods 0.000 description 16
- 230000004044 response Effects 0.000 description 16
- 201000011510 cancer Diseases 0.000 description 15
- OKEKLOJNCOIPIT-ZCOVNTAASA-N taxoline Chemical compound O([C@@H]1[C@]2(O)C[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]3(C)[C@H](O)C[C@H]4OC[C@]4([C@H]31)OC(C)=O)C2(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C(C)CC)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 OKEKLOJNCOIPIT-ZCOVNTAASA-N 0.000 description 14
- 229910052697 platinum Inorganic materials 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 208000004235 neutropenia Diseases 0.000 description 11
- 208000033808 peripheral neuropathy Diseases 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 231100000419 toxicity Toxicity 0.000 description 10
- 230000001988 toxicity Effects 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 210000001772 blood platelet Anatomy 0.000 description 8
- 206010013975 Dyspnoeas Diseases 0.000 description 7
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 7
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 7
- 230000000118 anti-neoplastic effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 206010037844 rash Diseases 0.000 description 7
- 208000010201 Exanthema Diseases 0.000 description 6
- 208000032843 Hemorrhage Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 201000005884 exanthem Diseases 0.000 description 6
- 210000003714 granulocyte Anatomy 0.000 description 6
- 239000008389 polyethoxylated castor oil Substances 0.000 description 6
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 5
- 229930182837 (R)-adrenaline Natural products 0.000 description 5
- 206010065553 Bone marrow failure Diseases 0.000 description 5
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 208000006218 bradycardia Diseases 0.000 description 5
- 229960005139 epinephrine Drugs 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 201000002364 leukopenia Diseases 0.000 description 5
- 231100001022 leukopenia Toxicity 0.000 description 5
- 230000007823 neuropathy Effects 0.000 description 5
- 201000001119 neuropathy Diseases 0.000 description 5
- 229960000620 ranitidine Drugs 0.000 description 5
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 5
- 208000001953 Hypotension Diseases 0.000 description 4
- 206010028813 Nausea Diseases 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 230000036543 hypotension Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000002045 lasting effect Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000008693 nausea Effects 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 3
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 3
- 208000024780 Urticaria Diseases 0.000 description 3
- 230000001387 anti-histamine Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 230000036471 bradycardia Effects 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 229960001380 cimetidine Drugs 0.000 description 3
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 3
- 229940047120 colony stimulating factors Drugs 0.000 description 3
- 229960000935 dehydrated alcohol Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000002489 hematologic effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 206010002199 Anaphylactic shock Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 206010049765 Bradyarrhythmia Diseases 0.000 description 2
- 206010055113 Breast cancer metastatic Diseases 0.000 description 2
- 208000002633 Febrile Neutropenia Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 208000001871 Tachycardia Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000009104 chemotherapy regimen Methods 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 230000009429 distress Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 231100000226 haematotoxicity Toxicity 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 238000011268 retreatment Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 230000006794 tachycardia Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- 206010003130 Arrhythmia supraventricular Diseases 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010015856 Extrasystoles Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 206010028817 Nausea and vomiting symptoms Diseases 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 208000025047 Non-histaminic angioedema Diseases 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010040738 Sinus arrest Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000009729 Ventricular Premature Complexes Diseases 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 206010047289 Ventricular extrasystoles Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 229940088007 benadryl Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229940124645 emergency medicine Drugs 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 208000011318 facial edema Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229930184616 taxin Natural products 0.000 description 1
- KOTXAHKUCAQPQA-AAUVPWARSA-N taxine Chemical compound C1([C@@H]([C@@H](O)C(=O)O[C@@H]2C=3/C[C@@](C([C@H](O)C4=C(C)[C@@H](OC(C)=O)CC(C4(C)C)[C@@H](OC(C)=O)\C=3)=O)(C)[C@@H](O)C2)N(C)C)=CC=CC=C1 KOTXAHKUCAQPQA-AAUVPWARSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 231100000155 toxicity by organ Toxicity 0.000 description 1
- 230000007675 toxicity by organ Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92362892A | 1992-08-03 | 1992-08-03 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE9301951D0 SE9301951D0 (sv) | 1993-06-08 |
| SE9301951L SE9301951L (sv) | 1994-02-07 |
| SE513082C2 true SE513082C2 (sv) | 2000-07-03 |
Family
ID=25448992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE9301951A SE513082C2 (sv) | 1992-08-03 | 1993-06-08 | Användning av taxol i infusionspreparat |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US5641803A (da) |
| EP (3) | EP0783886A3 (da) |
| JP (1) | JP2848760B2 (da) |
| AT (1) | ATE152910T1 (da) |
| AU (3) | AU3216893A (da) |
| BE (1) | BE1006497A5 (da) |
| CA (1) | CA2086874E (da) |
| CH (1) | CH686868A5 (da) |
| DE (2) | DE69310634T2 (da) |
| DK (2) | DK65293A (da) |
| ES (2) | ES2105926B1 (da) |
| FR (1) | FR2694192B1 (da) |
| GB (1) | GB9311740D0 (da) |
| GR (2) | GR1001617B (da) |
| IE (1) | IE80620B1 (da) |
| IL (1) | IL105879A (da) |
| IT (1) | IT1276041B1 (da) |
| MY (1) | MY109862A (da) |
| NL (1) | NL9301086A (da) |
| NZ (1) | NZ245795A (da) |
| PT (1) | PT101289A (da) |
| SE (1) | SE513082C2 (da) |
| ZA (1) | ZA93686B (da) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070117863A1 (en) * | 1993-02-22 | 2007-05-24 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
| US5886026A (en) * | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| USRE38424E1 (en) * | 1994-11-21 | 2004-02-10 | The United States Of America As Represented By The Department Of Health And Human Services | Method for treating taxol side-effects with G-CSF |
| EP0932399B1 (en) | 1996-03-12 | 2006-01-04 | PG-TXL Company, L.P. | Water soluble paclitaxel prodrugs |
| US6441025B2 (en) * | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
| US6495579B1 (en) | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
| US20030157187A1 (en) * | 1996-12-02 | 2003-08-21 | Angiotech Pharmaceuticals, Inc. | Compositions and methods for treating or preventing inflammatory diseases |
| US6515016B2 (en) | 1996-12-02 | 2003-02-04 | Angiotech Pharmaceuticals, Inc. | Composition and methods of paclitaxel for treating psoriasis |
| US6727280B2 (en) * | 1997-01-07 | 2004-04-27 | Sonus Pharmaceuticals, Inc. | Method for treating colorectal carcinoma using a taxane/tocopherol formulation |
| US6458373B1 (en) * | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| US20030087954A1 (en) * | 1997-01-07 | 2003-05-08 | Sonus Pharmaceuticals, Inc. | Method of treating bladder carcinoma using a Taxane/Tocopherol formulation |
| US20030105156A1 (en) * | 1997-01-07 | 2003-06-05 | Nagesh Palepu | Method for administration of a taxane/tocopherol formulation to enhance taxane therapeutic utility |
| GB9705903D0 (en) | 1997-03-21 | 1997-05-07 | Elliott Gillian D | VP22 Proteins and uses thereof |
| AU7486898A (en) | 1997-05-13 | 1998-12-08 | Stuart D Edwards | Global medical treatment method and apparatus |
| DK1023050T3 (da) * | 1997-06-27 | 2013-10-14 | Abraxis Bioscience Llc | Nye formuleringer af farmakologiske midler, fremgangsmåder til fremstillingen deraf og fremgangsmåder til anvendelsen deraf |
| SG165156A1 (en) | 1997-06-27 | 2010-10-28 | Abraxis Bioscience Llc | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| HUP9701554D0 (en) * | 1997-09-18 | 1997-11-28 | Human Oltoanyagtermeloe Gyogys | Pharmaceutical composition containing plazma proteins |
| EP0996461B1 (en) | 1997-10-31 | 2005-01-12 | Walter Reed Army Institute of Research | Use of a complement activation inhibitor in the manufacture of a medicament for inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules |
| KR20080016756A (ko) * | 1998-02-05 | 2008-02-21 | 노파르티스 아게 | 유기화합물 함유 조성물 |
| US6683100B2 (en) | 1999-01-19 | 2004-01-27 | Novartis Ag | Organic compounds |
| US6194181B1 (en) * | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
| US7030155B2 (en) * | 1998-06-05 | 2006-04-18 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| US6121029A (en) | 1998-06-18 | 2000-09-19 | Novartis Ag | Genes for the biosynthesis of epothilones |
| US6461637B1 (en) * | 2000-09-01 | 2002-10-08 | Neopharm, Inc. | Method of administering liposomal encapsulated taxane |
| US7314637B1 (en) | 1999-06-29 | 2008-01-01 | Neopharm, Inc. | Method of administering liposomal encapsulated taxane |
| US6017948A (en) * | 1998-10-30 | 2000-01-25 | Supergen, Inc. | Water-miscible pharmaceutical compositions |
| US6472420B2 (en) * | 1998-11-12 | 2002-10-29 | Cell Pathways, Inc. | Method for treating a patient with neoplasia by treatment with a paclitaxel derivative |
| US6235776B1 (en) * | 1998-11-12 | 2001-05-22 | Cell Pathways, Inc. | Method for treating a patient with neoplasia by treatment with a paclitaxel derivative |
| CA2371728C (en) * | 1999-06-11 | 2009-06-02 | Neorx Corporation | High dose radionuclide complexes for bone marrow suppression |
| TW422706B (en) | 1999-07-01 | 2001-02-21 | Wang Iz Rung | An oil-in-water emulsion type of paclitaxel |
| US7094885B2 (en) * | 1999-07-11 | 2006-08-22 | Neorx Corporation | Skeletal-targeted radiation to treat bone-associated pathologies |
| EP2266607A3 (en) | 1999-10-01 | 2011-04-20 | Immunogen, Inc. | Immunoconjugates for treating cancer |
| US20030054977A1 (en) * | 1999-10-12 | 2003-03-20 | Cell Therapeutics, Inc. | Manufacture of polyglutamate-therapeutic agent conjugates |
| US6828346B2 (en) * | 1999-10-25 | 2004-12-07 | Supergen, Inc. | Methods for administration of paclitaxel |
| US6136846A (en) | 1999-10-25 | 2000-10-24 | Supergen, Inc. | Formulation for paclitaxel |
| JP2001247459A (ja) | 2000-03-03 | 2001-09-11 | Oakland Uniservices Ltd | 癌の組み合わせ療法 |
| US20020077290A1 (en) * | 2000-03-17 | 2002-06-20 | Rama Bhatt | Polyglutamic acid-camptothecin conjugates and methods of preparation |
| US6569459B2 (en) | 2000-04-10 | 2003-05-27 | Teva Pharmaceutical Industries, Ltd. | Method of administration of paclitaxel-plasma protein formulation |
| AU2001282717A1 (en) | 2000-07-28 | 2002-02-13 | Cancer Research Technology Limited | Cancer treatment by combination therapy |
| WO2003079972A2 (en) | 2002-02-22 | 2003-10-02 | New River Parmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| JP2004536034A (ja) | 2001-01-08 | 2004-12-02 | ネオルクス コーポレイション | 治療的および診断的化合物、組成物および方法 |
| ATE481097T1 (de) | 2001-01-16 | 2010-10-15 | Vascular Therapies Llc | Implantierbare vorrichtung enthaltend resorbierbares matrixmaterial und antiproliferative wirkstoffe zur vorbeugung oder behandlung von versagen vaskulärer hämodialysezugänge und anderer vaskulärer transplantate |
| US7115565B2 (en) | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
| US6548531B2 (en) | 2001-02-09 | 2003-04-15 | Hoffmann-La Roche Inc. | Method for cancer therapy |
| US7666414B2 (en) * | 2001-06-01 | 2010-02-23 | Cornell Research Foundation, Inc. | Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen |
| US7514078B2 (en) | 2001-06-01 | 2009-04-07 | Cornell Research Foundation, Inc. | Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies |
| JP4619651B2 (ja) * | 2001-06-01 | 2011-01-26 | コーネル・リサーチ・ファンデーション・インコーポレイテッド | 前立腺特異的膜抗原に対する修飾抗体およびその使用 |
| GB0121285D0 (en) | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| US20030054042A1 (en) * | 2001-09-14 | 2003-03-20 | Elaine Liversidge | Stabilization of chemical compounds using nanoparticulate formulations |
| US20040191218A1 (en) * | 2001-09-26 | 2004-09-30 | Emlen James W | Pharmaceutical compositions and methods for treating cancer |
| CN1592607A (zh) * | 2001-10-15 | 2005-03-09 | 克里蒂泰克公司 | 水溶性差药物的组合物、其给药方法和治疗方法 |
| US20080220075A1 (en) * | 2002-03-20 | 2008-09-11 | Elan Pharma International Ltd. | Nanoparticulate compositions of angiogenesis inhibitors |
| CA2479665C (en) * | 2002-03-20 | 2011-08-30 | Elan Pharma International Ltd. | Nanoparticulate compositions of angiogenesis inhibitors |
| GB2386836B (en) | 2002-03-22 | 2006-07-26 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| WO2003086383A1 (en) * | 2002-04-12 | 2003-10-23 | Multimmune Gmbh | Non-toxic amounts of protein-aggregating substances stimulate hsp70 expression and function as anti-tumor agents |
| CA2484656A1 (en) * | 2002-05-10 | 2003-12-04 | Agennix Incorporated | Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases |
| CZ294371B6 (cs) * | 2002-06-10 | 2004-12-15 | Pliva - Lachema, A. S. | Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy |
| US20040047835A1 (en) * | 2002-09-06 | 2004-03-11 | Cell Therapeutics, Inc. | Combinatorial drug therapy using polymer drug conjugates |
| GB2394658A (en) | 2002-11-01 | 2004-05-05 | Cancer Rec Tech Ltd | Oral anti-cancer composition |
| EA200501252A1 (ru) * | 2003-02-03 | 2006-02-24 | Неофарм, Инк. | Липосомальная композиция, способ ее получения и лекарственное средство на ее основе (варианты) |
| EP1656124A1 (en) * | 2003-03-12 | 2006-05-17 | Cerenis | Methods and compositions for the treatment of cancer |
| US7085886B2 (en) * | 2003-05-28 | 2006-08-01 | International Buisness Machines Corporation | Autonomic power loss recovery for a multi-cluster storage sub-system |
| US20050208095A1 (en) * | 2003-11-20 | 2005-09-22 | Angiotech International Ag | Polymer compositions and methods for their use |
| WO2005094882A1 (en) * | 2004-03-03 | 2005-10-13 | Millennium Pharmaceuticals, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
| US7989490B2 (en) * | 2004-06-02 | 2011-08-02 | Cordis Corporation | Injectable formulations of taxanes for cad treatment |
| US8557861B2 (en) * | 2004-09-28 | 2013-10-15 | Mast Therapeutics, Inc. | Low oil emulsion compositions for delivering taxoids and other insoluble drugs |
| GB0501192D0 (en) * | 2005-01-20 | 2005-03-02 | Resolution Chemicals Ltd | Stable prostaglandin-containing compositions |
| CN103285395A (zh) * | 2005-02-18 | 2013-09-11 | 阿布拉科斯生物科学有限公司 | 治疗剂的组合和给予方式以及联合治疗 |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| US20070003557A1 (en) * | 2005-04-21 | 2007-01-04 | Andres Forero | Method for treating cancer using premedication |
| EP1896007B1 (en) * | 2005-05-04 | 2014-03-19 | Medigene AG | Method of administering a cationic liposomal preparation comprising paclitexel |
| TWI376239B (en) * | 2006-02-01 | 2012-11-11 | Andrew Xian Chen | Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof |
| EP2004175A4 (en) * | 2006-03-16 | 2010-12-15 | Bionumerik Pharmaceuticals Inc | COMPOUNDS AND FORMULATIONS FOR INCREASING THE EFFECT OF CANCER AND METHOD FOR THEIR USE |
| WO2007107305A2 (en) | 2006-03-22 | 2007-09-27 | Medigene Ag | Treatment of triple receptor negative breast cancer |
| WO2008004231A1 (en) * | 2006-07-07 | 2008-01-10 | Tiltan Pharma Ltd. | Anti-cancer therapy comprising an h2-blocker, at least one antiinflammatory agent and a cytotoxic agent |
| WO2008105852A2 (en) * | 2006-10-26 | 2008-09-04 | Creighton University | Mucoadhesive nanoparticles for cancer treatment |
| CN102014891B (zh) | 2008-03-14 | 2013-12-18 | 比奥纽默里克药物公司 | 增加癌症患者存活时间的化合物的组合物和使用方法 |
| JP5694782B2 (ja) | 2008-03-14 | 2015-04-01 | バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド | 肺癌、腺癌及び他の病状のための治療方法及び組成物 |
| MX2011009413A (es) | 2009-03-11 | 2011-10-21 | Ambit Biosciences Corp | Combinacion de una indazolilaminopirrolotriazina y taxano para tratamiento contra cancer. |
| CA2794147A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma |
| BR112012024442A2 (pt) | 2010-03-29 | 2017-03-21 | Abraxis Bioscience Llc | métodos de tratamento de câncer |
| EP3372617B1 (en) | 2010-04-02 | 2024-07-24 | Amunix Pharmaceuticals, Inc. | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same |
| RU2576609C2 (ru) | 2010-06-04 | 2016-03-10 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечение рака поджелудочной железы |
| TW202330606A (zh) | 2014-03-21 | 2023-08-01 | 美商艾伯維有限公司 | 抗-egfr抗體及抗體藥物結合物 |
| WO2017214339A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
| JP2019524651A (ja) | 2016-06-08 | 2019-09-05 | アッヴィ・インコーポレイテッド | 抗ｃｄ９８抗体及び抗体薬物コンジュゲート |
| CN109963870B (zh) | 2016-06-08 | 2023-07-28 | 艾伯维公司 | 抗b7-h3抗体和抗体药物偶联物 |
| CA3027044A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
| CN109562168A (zh) | 2016-06-08 | 2019-04-02 | 艾伯维公司 | 抗cd98抗体及抗体药物偶联物 |
| WO2018059304A1 (zh) | 2016-09-29 | 2018-04-05 | 四川科伦药物研究院有限公司 | 白蛋白药物组合物及其制备方法 |
| AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2601675B1 (fr) * | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent |
| FR2629818B1 (fr) * | 1988-04-06 | 1990-11-16 | Centre Nat Rech Scient | Procede de preparation du taxol |
| AU2005692A (en) * | 1991-05-08 | 1992-12-21 | United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Method for designing cancer treatment regimens and methods and pharmaceutical compositions for the treatment of cancer |
| FR2678833B1 (fr) * | 1991-07-08 | 1995-04-07 | Rhone Poulenc Rorer Sa | Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes. |
-
1993
- 1993-01-07 CA CA002086874A patent/CA2086874E/en not_active Expired - Fee Related
- 1993-01-29 AU AU32168/93A patent/AU3216893A/en not_active Abandoned
- 1993-01-29 AU AU32102/93A patent/AU641894B3/en not_active Ceased
- 1993-01-29 NZ NZ245795A patent/NZ245795A/xx not_active IP Right Cessation
- 1993-02-01 ZA ZA93686A patent/ZA93686B/xx unknown
- 1993-02-02 MY MYPI93000157A patent/MY109862A/en unknown
- 1993-06-02 IL IL10587993A patent/IL105879A/en not_active IP Right Cessation
- 1993-06-04 DK DK065293A patent/DK65293A/da not_active Application Discontinuation
- 1993-06-07 GB GB939311740A patent/GB9311740D0/en active Pending
- 1993-06-08 IE IE930433A patent/IE80620B1/en not_active IP Right Cessation
- 1993-06-08 SE SE9301951A patent/SE513082C2/sv not_active IP Right Cessation
- 1993-06-10 GR GR930100239A patent/GR1001617B/el not_active IP Right Cessation
- 1993-06-15 PT PT101289A patent/PT101289A/pt not_active Application Discontinuation
- 1993-06-22 NL NL9301086A patent/NL9301086A/nl not_active Application Discontinuation
- 1993-07-15 JP JP5174994A patent/JP2848760B2/ja not_active Expired - Lifetime
- 1993-07-19 ES ES09301618A patent/ES2105926B1/es not_active Expired - Fee Related
- 1993-07-29 EP EP97104512A patent/EP0783886A3/en not_active Withdrawn
- 1993-07-29 DK DK93401978.7T patent/DK0584001T3/da active
- 1993-07-29 EP EP93401978A patent/EP0584001B1/en not_active Revoked
- 1993-07-29 AT AT93401978T patent/ATE152910T1/de not_active IP Right Cessation
- 1993-07-29 IT IT93MI001714A patent/IT1276041B1/it active IP Right Grant
- 1993-07-29 FR FR9309372A patent/FR2694192B1/fr not_active Expired - Fee Related
- 1993-07-29 EP EP97104511A patent/EP0783885A3/en not_active Withdrawn
- 1993-07-29 DE DE69310634T patent/DE69310634T2/de not_active Revoked
- 1993-07-29 ES ES93401978T patent/ES2101261T3/es not_active Expired - Lifetime
- 1993-07-30 BE BE9300800A patent/BE1006497A5/fr active
- 1993-08-02 DE DE4325927A patent/DE4325927B4/de not_active Revoked
- 1993-08-03 CH CH02325/93A patent/CH686868A5/de not_active IP Right Cessation
-
1995
- 1995-10-18 US US08/544,594 patent/US5641803A/en not_active Expired - Lifetime
- 1995-11-20 US US08/559,890 patent/US5621001A/en not_active Expired - Lifetime
-
1996
- 1996-01-19 AU AU42070/96A patent/AU704393C/en not_active Ceased
- 1996-09-19 US US08/715,914 patent/US5670537A/en not_active Expired - Lifetime
- 1996-11-22 US US08/755,740 patent/US5665761A/en not_active Expired - Lifetime
-
1997
- 1997-08-13 GR GR970402058T patent/GR3024415T3/el unknown
-
2000
- 2000-02-07 US US09/499,373 patent/US6414014B1/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE513082C2 (sv) | Användning av taxol i infusionspreparat | |
| CN105705148B (zh) | 使用普那布林和紫杉烷的组合的癌症疗法 | |
| MX2008008723A (es) | Tratamiento de la hepatitis viral. | |
| JPS59112948A (ja) | コレステロ−ルレベル低下剤 | |
| CN105813637A (zh) | 用于治疗慢性疲劳综合征的可溶性鸟苷酸环化酶的激活剂或刺激剂 | |
| JP2013521338A (ja) | 小細胞肺癌を治療するための方法 | |
| Porter et al. | Iron chelation | |
| CN119894507A (zh) | 嵌合抗原受体（car）t细胞辅助疗法 | |
| GB2269319A (en) | Compositions containing taxol | |
| HK1001199A (en) | Use of taxol for the manufacture of a medicament for the treatment of cancer | |
| HK1001200A (en) | Use of taxol for the manufacture of a medicament for the treatment of cancer | |
| JP2012025734A (ja) | 骨髄異形性症候群を治療するための組成物および方法 | |
| WO2025209478A1 (en) | Methods of treatment warm autoimmune hemolytic anemia using sovleplenib | |
| TW202539688A (zh) | 使用索樂匹尼布處置溫型自體免疫性溶血性貧血的方法 | |
| AU7179200A (en) | Method of treatment of breast cancer | |
| WO2024158001A1 (ja) | イヌのｂ細胞リンパ腫の治療方法 | |
| CN114028374A (zh) | 富马酸二甲酯在制备用于保护胰岛β细胞功能的药物中的用途 | |
| CN118924745A (zh) | 奥美沙坦酯单药以及和索拉非尼联合疗法在预防/治疗糖尿病中的应用 | |
| IL34670A (en) | Pharmaceutical preparations containing 2-) 2,6-dichlorophenyl-amino (-1,3-diazacicopentane-) 2) and / or its acidic salt salts | |
| Stanley | Share this story: RELATED ARTICLES | |
| Dittrich et al. | Therapy of the small cell lung cancer—Comparison two established chemotherapy regime (ACO vs. CEV) | |
| HK1229712B (en) | Cancer treatment with combination of plinabulin and taxane | |
| JPH0867637A (ja) | 肝疾患予防治療薬 | |
| WO2013019222A1 (en) | Compositions and methods for treating myelodysplastic syndrome | |
| HK1185808B (en) | Combination therapy comprising vemurafenib and an interferon for use in the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |